臨床泌尿器科59巻7号

2005年06月発行

特集 手術によらない限局性前立腺癌の治療

前立腺小線源療法

著者： 門間哲雄¹ 斉藤史郎¹

所属機関： ¹独立行政法人国立病院機構　東京医療センター泌尿器科

ページ範囲：P.449 - P.455

要旨

　ヨウ素125を用いた小線源療法は低線量の放射性物質を前立腺内へ永久挿入する治療法であり，T2以下の限局性前立腺癌患者が適応となる。PSA 10ng/mリットル，Gleason score 6以下の症例は小線源単独治療となるが，それ以外には外照射の併用を行う。内分泌療法は前立腺容量が大きい症例に縮小目的として施行するのみで併用は行わない。治療成績は手術と同等とされるが，本治療の適応が早期癌であり比較はできない。他の治療法に比べて副作用は尿路・消化器症状ともに軽微で，特に性機能への影響は少ない。小線源の永久挿入による周囲への放射線被爆はきわめて少ないが，ガイドラインに準じた患者への適切な指導が必要である。

参考文献

1）Whitmore WF Jr, Hilaris B and Grabstald H：Retropubic implantation of iodine 125 in the treatment of prostatic cancer. J Urol 108：918-920, 1972

2）Holm HH, Juul N, Pedersen JF, et al：Transperi-neal ▲125▲iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 130：283-286, 1983.

3）Beyer D, Nath R, Butler W, et al：American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for（103）palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 47：273-275, 2000

4）Sylvester JE, Blasko JC, Grimm PD, et al：Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer：the Seattle experience. Int J Radiat Oncol Biol Phys 57：944-952, 2003

5）Lee LN, Stock RG and Stone NN：Role of hormonal therapy in the management of intermediate-to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52：444-452, 2002

6）Nag S, Beyer D, Friedland J, et al：American Brachytherapy Society（ABS）recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44：789-799, 1999

7）Peschel RE and Colberg JW：Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 4：233-241, 2003

8）Merrick GS, Butler WM, Wallner KE, et al：Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 64：754-759, 2004

9）Laverdiere J, Gomez JL, Cusan L, et al：Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37：247-252, 1997

10）Merrick GS, Butler WM, Galbreath RW, et al：Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? BJU Int 91：23-29, 2003

11）Kucway R, Vicini F, Huang R, et al：Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 167：2443-2447, 2002

12）Nag S, Ciezki JP, Cormack R, et al：Intraoperative planning and evaluation of permanent prostate brachytherapy：report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 51：1422-1430, 2001

13）Waterman FM and Dicker AP：Probability of late rectal morbidity in ▲125▲I prostate brachytherapy. Int J Radiat Oncol Biol Phys 55：342-353, 2003

14）Waterman FM, Yue N, Reisinger S, et al：Effect of edema on the post-implant dosimetry of an I-125 prostate implant：a case study. Int J Radiat Oncol Biol Phys 38：335-339, 1997

15）Grimm PD, Blasko JC, Sylvester JE, et al：10-year biochemical（prostate-specific antigen）control of prostate cancer with（125）I brachytherapy. Int J Radiat Oncol Biol Phys 51：31-40, 2001

16）Consensus statement：Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37：1035-1041, 1997

17）Brenner PC, Russo P, Wood DP, et al：Salvage radical prostatectomy in the management of locally recurrent prostate cancer after▲125▲I implantation. Br J Urol 75：44-47, 1995

18）Patel C, Elshaikh MA, Angermeier K, et al：PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 63：110-113, 2004

19）Blasko JC：Brachytherapy. Urology 55：306-308, 2000

20）Kollmeier MA, Stock RG and Stone N：Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up：importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57：645-659, 2003

21）Lederman GS, Cavanagh W, Albert PS, et al：Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 49：1297-1303, 2001

22）Kleinberg L, Wallner K, Roy J, et al：Treatment-related symptoms during the first year following transperineal▲125▲I prostate implantation. Int J Radiat Oncol Biol Phys 28：985-990, 1994

23）Desai J, Stock RG, Stone NN, et al：Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 6：135-141, 1998

24）Stone NN and Stock RG：Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate. Urol Clin North Am 30：351-362, 2003

25）Merrick GS, Butler WM, Wallner KE, et al：Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 58：81-88, 2004

26）Theodorescu D, Gillenwater JY and Koutrouvelis PG：Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 89：2085-2091, 2000

27）Merrick GS, Butler WM, Galbreath RW, et al：Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 52：893-902, 2002

28）Kang SK, Chou RH, Dodge RK, et al：Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 53：99-103, 2002

29）Eshleman JS, Davis BJ, Pisansky TM, et al：Radioactive seed migration to the chest after transper-ineal interstitial prostate brachytherapy：extraprostatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys 59：419-425, 2004